This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Randomized, Double-blind, Parallel, Placebo-cont...
Clinical trial

A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders To Or Intolerant Of TNF-? Antagonists

Read time: 1 mins
Last updated:14th Nov 2012
To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) is effective for: � reduction of signs and symptoms at week 24 and � improvement of physical function over 24 weeks in patients with active rheumatoid arthritis (RA) who are inadequate responders or intolerant to tumor necrosis factor alpha (TNF-?) antagonists
Category Value
Study start date 2012-11-14

View full details